{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-005581","form_type":"8-K","ticker":"APTOF","cik":"0000882361","company_name":"Aptose Biosciences Inc.","filed_at":"2025-08-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.569135+00:00","generated_at":"2026-05-17T10:28:17.440574+00:00","sec_items":["5.07","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Aptose Biosciences appoints EY as auditor and receives additional $1.5M from Hanmi for tuspetinib","bullets":["Shareholders voted 96.95% in favor of appointing Ernst & Young LLP as independent registered public accounting firm.","Received an additional US$1.5M advance from Hanmi Pharmaceutical under the existing US$8.5M loan facility.","Total advances under the loan facility now US$7.1M to support clinical development of tuspetinib.","Funds will be used to continue development of tuspetinib-based triple drug frontline therapy for newly diagnosed AML."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-005581","json":"https://secwatch.observer/filing/0001171843-25-005581.json","markdown":"https://secwatch.observer/filing/0001171843-25-005581.md","text":"https://secwatch.observer/filing/0001171843-25-005581.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882361/000117184325005581/0001171843-25-005581-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882361/000117184325005581/f8k_082525.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T10:28:17.440574+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}